Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
C608570-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,258.90 | |
C608570-25mg | 25mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $4,000.90 |
Synonyms | CIPRALISANT | Cipralisant [INN] | 213027-19-1 | GT-2331 | Cipralisant, (-)- | 309713XSKW | UNII-309713XSKW | CHEMBL278462 | 5-[(1R,2R)-2-(5,5-dimethylhex-1-ynyl)cyclopropyl]-1H-imidazole | (-)-GT-2331 | 4-((1R,2R)-2-(5,5-Dimethylhex-1-ynyl)cyclopropyl)-1H-imidazole | GTPL1244 | |
---|---|
Specifications & Purity | Moligand™ |
Grade | Moligand™ |
Action Type | AGONIST |
Mechanism of action | Agonist of H 3 receptor |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
IUPAC Name | 5-[(1R,2R)-2-(5,5-dimethylhex-1-ynyl)cyclopropyl]-1H-imidazole |
---|---|
INCHI | InChI=1S/C14H20N2/c1-14(2,3)7-5-4-6-11-8-12(11)13-9-15-10-16-13/h9-12H,5,7-8H2,1-3H3,(H,15,16)/t11-,12-/m1/s1 |
InChi Key | CVKJAXCQPFOAIN-VXGBXAGGSA-N |
Canonical SMILES | CC(C)(C)CCC#CC1CC1C2=CN=CN2 |
Isomeric SMILES | CC(C)(C)CCC#C[C@@H]1C[C@H]1C2=CN=CN2 |
Alternate CAS | 213027-19-1 |
PubChem CID | 6450823 |
MeSH Entry Terms | 4-(2-(5,5-dimethylhex-1-ynyl)cyclopropyl)imidazole;GT 2331;GT-2331 |
PubChem CID | 6450823 |
---|---|
Wikipedia | Cipralisant |
CAS Registry No. | 213027-19-1 |
ChEMBL Ligand | CHEMBL278462 |
GPCRdb Ligand | cipralisant |
Enter Lot Number to search for COA:
1. Krueger KM, Witte DG, Ireland-Denny L, Miller TR, Baranowski JL, Buckner S, Milicic I, Esbenshade TA, Hancock AA. (2005) G protein-dependent pharmacology of histamine H3 receptor ligands: evidence for heterogeneous active state receptor conformations.. J Pharmacol Exp Ther, 314 (1): (271-81). [PMID:15821027] |